Budesonide Inhalant
Product Images NDC 50090-7173

Product Visual Gallery

This gallery contains 6 technical images submitted to the FDA as part of the official labeling for Budesonide (NDC 50090-7173). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by A-s Medication Solutions, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Figure 1: A 12-week Trial In Pediatric Patients Not On Inhaled Corticosteroid Therapy Prior To Study Entry. Nighttime Asthma Change From Baseline (Bud Fig 1)

A line graph showing mean change from baseline in mean airway symptom scores over a 12-week period. The graph compares placebo with three dosages of the drug (0.25 mg, 0.5 mg, and 1.0 mg once daily), illustrating symptom improvement over time. P-values for each drug dose versus placebo are included below the graph.*

FDA Label Image

Figure 3: A 12-week Trial In Pediatric Patients Either Maintained On Bronchodilators Alone Or Inhaled Corticosteroid Therapy Prior To Study Entry. Nighttime Asthma Change From Baseline. (Bud Fig 3)

A line graph showing mean change from baseline in nighttime asthma symptoms over a 12-week period for Budesonide inhalant at doses 0.25 mg once daily, 0.25 mg twice daily, 0.5 mg thrice daily, 1.0 mg once daily, and a placebo. The y-axis shows mean symptom change, with all treatment groups generally showing greater symptom reduction than placebo over time.*

FDA Label Image

Chemical Structure (Budesonide 01)

Chemical structure of Budesonide showing its multi-ring steroid framework with oxygen-containing functional groups including hydroxyl, ketone, and ether groups, alongside an additional small organic moiety with oxygen atoms connected via dashed lines representing stereochemistry.*

FDA Label Image

Figure 1 (Budesonide 02)

A line graph depicting mean change from baseline in nighttime asthma symptoms over a 12-week period. The x-axis shows time intervals from baseline through week 12, while the y-axis measures mean change. Three lines represent placebo, 0.25 mg twice daily, and 0.5 mg twice daily doses, showing differing trends in symptom change over time.*

FDA Label Image

Ifu (Ifu 04 2020 Update)

An instructional diagram showing step-by-step visual and text guidance for using a budesonide inhalation suspension nebulizer. The illustrations depict assembling the nebulizer, removing and shaking the ampule, opening it by twisting off the top, and squeezing the contents into the nebulizer cup, with detailed instructions alongside each image.*

FDA Label Image

Label Image (Lbl500907173)

Budesonide 0.25 mg/2 mL inhalation suspension label from A-S Medication Solutions. The label details the product as an inhalant suspension with each unit delivering 0.25 mg/2 mL of budesonide. It includes storage instructions, packaging information (2 mL plastic sterile unit-dose ampules, 30 ampules total), lot number, and distributor information from A-S Medication Solutions in Libertyville, Illinois.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.